MYCN and neuroblastoma: In addition, targeting BRD4 by BET inhibitor displaces BRD4 from the MYCN promoter region and downregulates MYCN expression in neuroblastoma cells, establishing BRD4 as a transcriptional regulator of MYCN (8).